Contribution of Rennin-angiotensin System to the Maintenance of Tissue Hemostasis in Various Cell Populations

There have been presented the data of rennin-angiotensin system (RAS) contribution to the maintenance of tissue hemostasis in various cell populations in an experiment and clinical conditions. There have been given the findings confirming the effect of the system on the processes of cell division directly, and not on account of arterial pressure change. There have been observed universal responses on the administration of RAS effector peptides of various cell populations including those being unrelated to cardiovascular system and those being other than target organs for RAS components. There has been shown the ability of RAS components to normalize the proliferation of gastric mucosa in an experiment and on clinical material. RAS role in maintaining structural hemostasis has been discussed.

1. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells — implications in cardiovascular disease. Braz J Med Biol Res 2004 August; 37(8): 1263–1273.
2. Lemari C.A., Schiffrin E.L. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010 Mar; 11(1): 19–31.
3. Jenrow K.A. et al. Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. Radiat Oncol 2010 Feb; 1(5): 6.
4. Tsai C.T. et al. Interaction of gender, hypertension, and the angiotensinogen gene haplotypes on the risk of coronary artery disease in a large angiographic cohort. Atherosclerosis 2009 Mar; 203(1): 249–256.
5. Garcia P. et al. Inhibition of angiotensin–converting enzyme stimulates fracture healing and periosteal callus formation — role of a local rennin-angiotensin system. Br J Pharmacol 2010 Apr; 159(8): 1672–1680.
6. Bindom S.M. et al. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 2010 Oct; 59(10): 2540–2548.
7. Paizis G. et al. Up–regulation of components of the rennin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667–1676.
8. Ibrahim J., Hughes A.D., Sever P.S. Action of angiotensin II on DNA synthesis by human saphenous vein in organ culture. Hypertension 2000; 36(5): 917–921.
9. Diep Q.N. et al. Struture, endothelial fanction, cell growth and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105(19): 2296–2302.
10. Hong H.J., Liu J.C., Cheng T.H., Chan P. Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes. Acta Pharmacol Sin 2010 Dec; 31(12): 1569–1575.
11. Rodgers K.E., Xiong S., Steer R., diZerega G.S. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18(4): 287–294.
12. Vlahakos D.V., Marathias K.P., Madias N.E. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010 Sep; 56(3): 558–565.
13. Steckelings U.M. et al. Angiotensin II stimulates proliferation of primary human keratinocytes via a non-AT1, non-AT2 angiotensin receptor. Biochem Biophys Res Commun 1996 Dec 4; 229(1): 329–333.
14. Zeeli T. et al. Vitamin D inhibits captopril-induced cell detachment and apoptosis in keratinocytes. Br J Dermatol 2011 Jan; 164(1): 62–67.
15. Hiruma Y., Inoue A., Hirose S., Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun 1997 Jan 3; 230(1): 176–178.
16. Shimizu H. et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008 Jul; 22(7): 2465–2475.
17. Meijering B.D. et al. TGF-beta inhibits Ang II-induced MAPK p44/42 signaling in vascular smooth muscle cells by Ang II type 1 receptor downregulation. J Vasc Res 2009; 46(5): 459–468.
18. Marsh S.A., Dell’italia L.J., Chatham J.C. Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 2011 Mar; 40(3): 819–828.
19. Goette A. et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008 Feb 12; 117(6): 732–742.
20. Timmermans P.B. et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205–251.
21. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007 Jan; 292(1): 82–97.
22. Berry C. et al. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281(6): H2337–H2365.
23. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006 May; 20(5): 953–970.
24. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264(3): 224–236.
25. Pickel L. et al. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther 2010 Feb 16; 9(4): 277–285.
26. Abadir P.M. The frail rennin-angiotensin system. Clin Geriatr Med 2011 Feb; 27(1): 53–65.
27. Fujiyama S. et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circulation research 2001; 88(1): 22–29.
28. Silvestre J.S. et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circulation research 2002; 90(10): 1072–1079.
29. Stoll M. et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. The journal of clinical investigation 1995; 95(2): 651–657.
30. Bachelor M.A., Bowden G. Ultraviolet A–induced modulation of Bcl–XL by p38 MAPK in human keratinocytes: post-transcriptional regulation through the 3’-untranslated region. J Biol Chem 2004. 279: 42658–42668.
31. Alvarez S.E. et al. Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT2 receptors in rat fetal tissues. J Cell Biochem 2008; 105: 703–711.
32. Arnguiz-Urroz P. et al. Differential participation of angio­tensin II type 1 and 2 receptors in the regulation of cardiac cell death triggered by angiotensin II. Am J Hypertens 2009 May; 22(5): 569–576.
33. Song H. et al. Angiotensin II-mediated apoptosis on human vascular smooth muscle cells. J Cardiothorac Ren Res 2006; 1: 135–139.
34. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the rennin-angiotensin system. Circulation 2004; 109: 8–13.
35. Tan N.Y., Li J.M., Stocker R., Khachigian L.M. Angiotensin II-inducible smooth muscle cell apoptosis involves the angiotensin ii type 2 receptor, GATA-6 activation, and FasL-Fas engagement. Circulation Research 2009; 105: 422.
36. Li H. et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther 2009 Dec; 8(12): 3255–3265.
37. Horiuchi M., Akishita M., Dzau V.J. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocr Res 1998; 24: 307–314.
38. Cui T. et al. Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res 2001; 49: 863–871.
39. Lee Y.H., Marquez A.P., Mungunsukh O., Day R.M. Hepatocyte growth factor inhibits apoptosis by the profibrotic factor angiotensin II via extracellular signal-regulated kinase 1/2 in endothelial cells and tissue explants. Mol Biol Cell 2010 Dec; 21(23): 4240–4250.
40. Dhalla N.S., Temsah R.M. Sarcoplasmic reticulum and cardiac oxidative stress: an emerging target for heart disease. Expert Opin Ther Targets 2001 Apr; 5(2): 205–217.
41. Wu L.Y., Dang X.Q., He X.J., Yi Z.W. Effects of clearance of superoxide anion by catechin on the expression of NO and eNOS and apoptosis in endothelial progenitor cells induced by angiotensin II. Zhongguo Dang Dai Er Ke Za Zhi 2009 Jun; 11(6): 476–480.
42. Schiffrin E.L. Antioxidants in hypertension and cardiovascular disease. Mol Interv 2010 Dec; 10(6): 354–362.
43. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006 May; 20(5): 953–970.
44. Kosaka T. et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007; 67(1): 41–49.
45. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16(7): 293–299.
46. Ager E.I., Neo J., Christophi C. The rennin-angiotensin system and malignancy. Carcinogenesis 2008; 29(9): 1675–1684.
47. Yasumatsu R. et al. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 2004; 130: 567–573.
48. Ronquist G. et al. Association between captopril, other anti­hypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50–56.
49. Herath C.B. et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis. J Hepatol 2007; 47: 387–395.
50. Sugimoto M. et al. Role of angiotensinogen gene polymorphism on Helicobacter pylori infection–related gastric cancer risk in Japanese. Carcinogenesis 2010; 8(9): 2036–2040.
51. Sansom S.E. et al. miR–802 regulates human angiotensin II type 1 receptor expression in intestinal epithelial C2BBe1 cells. Am J Physiol Gastrointest Liver Physiol 2010 Sep; 299(3): 632–642.
52. Heinemann A. et al. Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow. Aliment Pharmacol Ther 1999 Mar; 13(3): 347–355.
53. Hallersund P., Elfvin A., Helander H.F., Findriks L. The expression of rennin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst 2011 Mar; 12(1): 54–64.
54. Laudanno O.M., Cesolari J.A. Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs. Acta Gastroenterol Latinoam 2006 Jun; 36(2): 76–80.
55. Zhivotova E.Yu., Timoshin S.S., Goncharova E.N., Fleyshman M.Yu. Bull Eksp Biol Med 1998; 126(12): 643–645.
56. Timoshin S.S., Zhivotova E.Yu. Bull Eksp Biol Med 2000; 129(2): 214–216.
57. Avilova A., Fleishman M., Jivotova E. et al. Does angio­tensin II affect cellular growth in gastric mucosa? Br J Clin Pharmacol 2002; 53: 447–448.
58. Mac D., Willis P., Lamonby S., Lynch D. Cellproliferation in type C gastritis affecting the intact stomach. J Clin Pathol 2000; 53(10): 784–787.
59. Alekseenko S.A., Timoshin S.S. Klin med 1996; 9: 52–54.
60. Rubio C.A. Plugs clog the glandular outlets in fundic gland polyps. Int J Clin Exp Pathol 2009 Sep; 10; 3(1): 69–74.
61. Aruin L.I., Kapuller L.L., Isakov V.A. Morfogeneticheskaya diagnostika bolezney zheludka i kishechnika [Morphogenetic diagnostics of gastric and intestinal diseases]. Moscow: Triada; 1998: 174.
62. Sazonova E.N., Zhivotova E.Yu. et al. Bull Eksp Biol Med 1999; 6: 288–291.
63. Mel’nikova N.P., Timoshin S.S. Bull Eksp Biol Med 2002; 134(7): 188–191.
64. Zhivotova E.Yu. et al. Bull Eksp Biol Med 2007; 9: 288–291.
65. Bolonyaeva N.A., Zhivotova E.Yu. et al. Dal’nevostochn meditsinskiy zhurnal 2005; 2: 62–66.
66. Zhivotova E.Yu. et al. Bull Eksp Biol Med 2009; 4: 422–426.
67. Fleyshman M.Yu., Zhivotova E.Yu. et al. Bull Eksp Biol Med 2009; 7: 72–75.

Zhivotova Е.Y., Timoshin S.S. Contribution of Rennin-angiotensin System to the Maintenance of Tissue Hemostasis in Various Cell Populations. Sovremennye tehnologii v medicine 2011; (4): 120